Nasonex Aquosum (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal passages. This binding alters gene transcription, leading to reduced production of inflammatory cytokines and mediators, decreased vascular permeability, and ultimately less swelling and irritation in the nasal mucosa.

The appropriate dose of Nasonex Aquosum is determined by the prescribing healthcare professional based on the patient’s age, condition severity and response to therapy. Patients should follow the prescriber’s instructions and the product’s labeling for proper use.

Safety data for mometasone furoate in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Nasonex Aquosum contains mometasone furoate, a high‑potency glucocorticoid with low systemic absorption, offering effective symptom control with a favorable safety profile. Compared with older nasal steroids such as beclomethasone, it often requires once‑daily dosing and may provide greater anti‑inflammatory potency.

Store Nasonex Aquosum at room temperature, below 25 °C, in its original packaging. Protect the container from moisture and direct sunlight. Do not freeze the product. Keep the spray tip clean and avoid contaminating the nozzle.

The spray is intended for intranasal use. The patient should gently blow the nose, insert the tip into one nostril, close the opposite nostril, and spray the prescribed number of puffs while breathing in gently. The process is repeated in the other nostril as directed.

Serious risks include adrenal suppression, especially with prolonged high‑dose use or concomitant systemic steroids, and ocular complications such as glaucoma or cataract formation. Rarely, severe allergic reactions or fungal infections of the sinus may occur, requiring immediate medical attention.

Patients with known hypersensitivity to mometasone furoate or any component of the formulation should avoid the product. It is also contraindicated in individuals with untreated bacterial, fungal or viral infections of the nasal passages, and in those for whom systemic corticosteroid exposure is contraindicated.